{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:16:20Z","timestamp":1790810180658,"version":"4.1.0"},"reference-count":216,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["02-01-02-SF1329"],"award-info":[{"award-number":["02-01-02-SF1329"]}],"id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.01624","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:28:44Z","timestamp":1600388924000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":393,"title":["Colorectal Cancer Immunotherapy: Options and Strategies"],"prefix":"10.3389","volume":"11","author":[{"given":"Nor Adzimah","family":"Johdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur Fazilah","family":"Sukor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin."},{"key":"B2","author":"Ferlay","year":"2019","journal-title":"Global Cancer Observatory: Cancer Today."},{"key":"B3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3322\/caac.21395","article-title":"Colorectal cancer statistics, 2017.","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin."},{"key":"B4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/gutjnl-2015-310912","article-title":"Global patterns and trends in colorectal cancer incidence and mortality.","volume":"66","author":"Arnold","year":"2016","journal-title":"Gut."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1093\/annonc\/mds236","article-title":"ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making.","volume":"23","author":"Schmoll","year":"2012","journal-title":"Ann Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/annonc\/mdu260","article-title":"Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.","author":"Van Cutsem","year":"2014","journal-title":"Ann Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdx738","article-title":"Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: A JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.","volume":"29","author":"Yoshino","year":"2018","journal-title":"Ann Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa1414882","article-title":"A randomized trial of laparoscopic versus open surgery for rectal cancer.","volume":"372","author":"Bonjer","year":"2015","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0140-6736(93)90207-W","article-title":"Mesorectal excision for rectal cancer.","volume":"341","author":"MacFarlane","year":"1993","journal-title":"Lancet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/DCR.0000000000001058","article-title":"Phase II clinical trial to evaluate the efficacy of transanal endoscopic total mesorectal excision for rectal cancer.","volume":"61","author":"Park","year":"2018","journal-title":"Dis Colon Rectum."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3322\/caac.21565","article-title":"Cancer treatment and survivorship statistics, 2019.","author":"Miller","year":"2019","journal-title":"CA Cancer J Clin."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/bjc.2012.421","article-title":"Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis.","volume":"107","author":"Garg","year":"2012","journal-title":"Br J Cancer."},{"key":"B14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1177\/1078155216647202","article-title":"5-fluorouracil toxicity in the treatment of colon cancer associated with the genetic polymorphism 2846 A>G (rs67376798).","volume":"23","author":"Gonz\u00e1lez-Perera","year":"2017","journal-title":"J Oncol Pharm Pract."},{"key":"B15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1200\/JCO","article-title":"Neoadjuvant (Chemo)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: results of the multicenter lateral node study of patients with low cT3\/4 rectal cancer.","volume":"37","author":"Ogura","year":"2018","journal-title":"J Clin Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment.","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/B978-0-12-800267-4.00003-1","article-title":"Recognition of tumors by the innate immune system and natural killer cells.","volume":"122","author":"Marcus","year":"2014","journal-title":"Adv Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer.","volume":"29","author":"Vesely","year":"2011","journal-title":"Annu Rev Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-017-0453-8","article-title":"Immunotherapy in hematologic malignancies: past, present, and future.","volume":"10","author":"Im","year":"2017","journal-title":"J Hematol Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.3747\/co.25.3840","article-title":"Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges.","volume":"25","author":"Nixon","year":"2018","journal-title":"Curr Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1055\/s-0029-1196806","article-title":"Ueber die z\u00fcchtung der erysipelkokken auf k\u00fcnstlichem n\u00e5hrboden und ihre uebertragbarkeit auf den menschen.","volume":"8","author":"Fehleisen","year":"1882","journal-title":"Dtsch Med Wochenschr."},{"key":"B22","article-title":"Aus der sitzung der medicinischen section vom 13 November 1867.","volume":"5","author":"Busch","year":"1868","journal-title":"Berlin Klin Wochenschr."},{"key":"B23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/00000658-189112000-00015","article-title":"II. Contribution to the knowledge of sarcoma.","volume":"14","author":"Coley","year":"1891","journal-title":"Ann Surg"},{"key":"B24","first-page":"154","article-title":"The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas.","volume":"26","author":"McCarthy","year":"2006","journal-title":"Iowa Orthop J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1534735419827090","article-title":"Immunotherapy of cancer: Developments and reference points, an unorthodox approach.","volume":"18","author":"Nikolaou","year":"2019","journal-title":"Integr Cancer Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/003591571000301601","article-title":"The treatment of inoperable sarcoma by bacterial toxins (The mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus).","volume":"3","author":"Coley","year":"1910","journal-title":"Proc R Soc Med."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02965","article-title":"The intriguing history of cancer immunotherapy.","volume":"10","author":"Dobosz","year":"2019","journal-title":"Front Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000386035","article-title":"The concept of immunological surveillance.","volume":"13","author":"Burnet","year":"1970","journal-title":"Prog Exp Tumor Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/oxfordjournals.bmb.a070310","article-title":"Immunological factors in the process of carcinogenesis.","volume":"20","author":"Burnet","year":"1964","journal-title":"Br Med Bull."},{"key":"B30","first-page":"1561","article-title":"Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host.","volume":"20","author":"Klein","year":"1960","journal-title":"Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference. I. The interferon.","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proc R Soc London Ser B Biol Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/00006534-195911000-00016","article-title":"The effect of vaccine on cancer patients.","volume":"109","author":"Graham","year":"1959","journal-title":"Surg Gynecol Obstet."},{"key":"B33","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/214992a0","article-title":"Cellular basis of the immunological defects in thymectomized mice.","volume":"214","author":"Miller","year":"1967","journal-title":"Nature."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1084\/jem.137.5.1142","article-title":"Identification of a novel cell type in peripheral lymphoid organs of mice: I. Morphology, quantitation, tissue distribution.","volume":"137","author":"Steinman","year":"1973","journal-title":"J Exp Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/eji.1830050208","article-title":"Natural killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype.","volume":"5","author":"Kiessling","year":"1975","journal-title":"Eur J Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/eji.1830050209","article-title":"Natural killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell.","volume":"5","author":"Kiessling","year":"1975","journal-title":"Eur J Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity.","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature."},{"key":"B38","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily-CTLA-4.","volume":"328","author":"Brunet","year":"1988","journal-title":"Nature."},{"key":"B39","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma.","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood."},{"key":"B40","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/jnci\/85.8.622","article-title":"Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.","volume":"85","author":"Rosenberg","year":"1993","journal-title":"JNCI J Natl Cancer Inst."},{"key":"B41","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer.","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma.","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma.","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma.","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5020-3","article-title":"The 2018 Nobel Prize in medicine goes to cancer immunotherapy (editorial for BMC cancer).","volume":"18","author":"Guo","year":"2018","journal-title":"BMC Cancer."},{"key":"B47","doi-asserted-by":"publisher","first-page":"12472","DOI":"10.18632\/oncotarget.2998","article-title":"Classification of current anticancer immunotherapies.","volume":"5","author":"Galluzzi","year":"2014","journal-title":"Oncotarget."},{"key":"B48","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/nrd984","article-title":"Therapeutic antibodies for human diseases at the dawn of the twenty-first century.","volume":"2","author":"Brekke","year":"2003","journal-title":"Nat Rev Drug Discov."},{"key":"B49","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/eji.1830060713","article-title":"Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion.","volume":"6","author":"K\u00f6hler","year":"1976","journal-title":"Eur J Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1126\/science.4001944","article-title":"Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface.","volume":"228","author":"Smith","year":"1985","journal-title":"Science."},{"key":"B51","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/978-1-62703-586-6_8","article-title":"Chimeric antibodies.","volume":"1060","author":"Kurosawa","year":"2014","journal-title":"Methods Mol Biol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases.","volume":"27","author":"Lu","year":"2020","journal-title":"J Biomed Sci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/protein\/4.7.773","article-title":"Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation.","volume":"4","author":"Kettleborough","year":"1991","journal-title":"Protein Eng."},{"key":"B54","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies.","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat Rev Drug Discov."},{"key":"B55","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/ilar.46.3.258","article-title":"Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources.","volume":"46","author":"Lipman","year":"2005","journal-title":"ILAR Journal."},{"key":"B56","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/ijc.2910110327","article-title":"Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen.","volume":"11","author":"Buben\u00edk","year":"1973","journal-title":"Int J Cancer."},{"key":"B57","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/1097-0142(19850801)56:33.0.co;2-2","article-title":"Specific active immunotherapy in patients with adenocarcinoma of the colon utilizing tumor-associated antigens (TAA). A phase I clinical trial.","volume":"56","author":"Hollinshead","year":"1985","journal-title":"Cancer."},{"key":"B58","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/bjc.1973.13","article-title":"A common tumour specific antigen.","volume":"27","author":"Dickinson","year":"1973","journal-title":"Br J Cancer."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1078-0432.CCR-08-2227","article-title":"Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer.","volume":"15","author":"Speetjens","year":"2009","journal-title":"Clin Cancer Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"p. 107","DOI":"10.1016\/B978-0-12-812630-1.00007-4","author":"Alatrash","year":"2019","journal-title":"Tumor-Associated Antigens. Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation."},{"key":"B61","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1158\/0008-5472.CAN-06-2112","article-title":"Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: implications for self-tolerance and tumor therapy.","volume":"67","author":"Cloosen","year":"2007","journal-title":"Cancer Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.3390\/cancers3022554","article-title":"State of the art in tumor antigen and biomarker discovery.","volume":"3","author":"Even-Desrumeaux","year":"2011","journal-title":"Cancers (Basel)."},{"key":"B63","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1034\/j.1600-065X.2002.18803.x","article-title":"Cancer\/testis antigens: an expanding family of targets for cancer immunotherapy.","volume":"188","author":"Scanlan","year":"2002","journal-title":"Immunol Rev."},{"key":"B64","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/CJI.0000000000000119","article-title":"MAGE-A is more highly expressed than NY-ESO-1 in a systematic immunohistochemical analysis of 3668 cases.","volume":"39","author":"Kerkar","year":"2016","journal-title":"J Immunother."},{"key":"B65","doi-asserted-by":"publisher","first-page":"68448","DOI":"10.18632\/oncotarget.19497","article-title":"Melanoma antigen A12 regulates cell cycle via tumor suppressor p21 expression.","volume":"8","author":"Yanagi","year":"2017","journal-title":"Oncotarget."},{"key":"B66","first-page":"1","article-title":"MAGE-A3 is highly expressed in a subset of colorectal cancer patients.","volume":"12","author":"Santha Kumara","year":"2012","journal-title":"Cancer Immun."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.5301\/ijbm.5000284","article-title":"EpCAM-expressing circulating tumor cells in colorectal cancer.","volume":"32","author":"Nicolazzo","year":"2017","journal-title":"Int J Biol Markers."},{"key":"B68","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/bjc.1994.173","article-title":"Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma.","volume":"69","author":"Starzynska","year":"1994","journal-title":"Br J Cancer."},{"key":"B69","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00262-018-2266-1","article-title":"The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: Implications for vaccine design.","volume":"68","author":"Besneux","year":"2019","journal-title":"Cancer Immunol Immunother."},{"key":"B70","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/jso.23503","article-title":"Evaluating the significance of expression of CEA mRNA and levels of CEA and its related proteins in colorectal cancer patients.","volume":"109","author":"Wang","year":"2014","journal-title":"J Surg Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.4161\/hv.29475","article-title":"Overexpressed oncogenic tumor-self antigens.","volume":"10","author":"Bright","year":"2014","journal-title":"Hum Vaccines Immunother."},{"key":"B72","first-page":"95","article-title":"Detection of EGFR expression in patients with colorectal cancer and the therapeutic effect of cetuximab.","volume":"21","author":"Liu","year":"2016","journal-title":"J BUON."},{"key":"B73","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3892\/mmr.2017.7860","article-title":"Overexpression of CCDC34 in colorectal cancer and its involvement in tumor growth, apoptosis and invasion.","volume":"17","author":"Geng","year":"2018","journal-title":"Mol Med Rep."},{"key":"B74","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.26355\/eurrev_201807_15505","article-title":"Aberrant expression of Rab1A and its prognostic significance in human colorectal cancer.","volume":"22","author":"Wang","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.955684","article-title":"Tumor antigen-targeting monoclonal antibody-based immunotherapy: orchestrating combined strategies for the development of long-term antitumor immunity.","volume":"3","author":"Michaud","year":"2014","journal-title":"Oncoimmunology."},{"key":"B76","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer.","volume":"12","author":"Scott","year":"2012","journal-title":"Nat Rev Cancer."},{"key":"B77","year":"2019","journal-title":"BIOPHARMA<sup>\u00ae<\/sup>: Biopharmaceutical Products in the U.S. and European Markets."},{"key":"B78","year":"2019","journal-title":"Resources for Information on Approved Drugs."},{"key":"B79","year":"2019"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1101\/gad.314617.118","article-title":"Roles of the immune system in cancer: From tumor initiation to metastatic progression.","volume":"32","author":"Gonzalez","year":"2018","journal-title":"Genes Dev."},{"key":"B81","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1053\/j.seminoncol.2015.05.003","article-title":"Cancer and immune system: basic concepts and targets for intervention.","volume":"42","author":"Pardoll","year":"2015","journal-title":"Semin Oncol."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and Anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations.","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/82_2017_62","article-title":"Tim-3, Lag-3, and TIGIT.","volume":"410","author":"Joller","year":"2017","journal-title":"Curr Top Microbiol Immunol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1002\/eji.200526090","article-title":"Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells.","volume":"35","author":"Kisielow","year":"2005","journal-title":"Eur J Immunol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-15-2626","article-title":"T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients.","volume":"22","author":"Kong","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.","volume":"415","author":"Monney","year":"2002","journal-title":"Nature."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11894-019-0674-9","article-title":"Back to the colorectal cancer consensus molecular subtype future.","volume":"21","author":"Menter","year":"2019","journal-title":"Curr Gastroenterol Rep."},{"key":"B88","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.critrevonc.2016.11.007","article-title":"Clinical relevance of colorectal cancer molecular subtypes.","volume":"109","author":"Rodriguez-Salas","year":"2017","journal-title":"Crit Rev Oncol Hematol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.17179\/excli2018-1455","article-title":"Simplified MSI marker panel for diagnosis of colorectal cancer.","volume":"12","author":"Shemirani","year":"2011","journal-title":"Asian Pac J Cancer Prev."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11864-015-0348-2","article-title":"Microsatellite instability testing and its role in the management of colorectal cancer.","volume":"16","author":"Kawakami","year":"2015","journal-title":"Curr Treat Options Oncol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"159","DOI":"10.17179\/excli2017-948","article-title":"Microsatellite instability in colorectal cancer.","volume":"17","author":"Nojadeh","year":"2018","journal-title":"EXCLI J."},{"key":"B92","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.celrep.2016.03.075","article-title":"Genomic correlates of immune-cell infiltrates in colorectal carcinoma.","volume":"15","author":"Giannakis","year":"2016","journal-title":"Cell Rep."},{"key":"B93","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer.","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089263","article-title":"T cell receptor signaling can directly enhance the avidity of CD28 ligand binding.","volume":"9","author":"Sanchez-Lockhart","year":"2014","journal-title":"PLoS One"},{"key":"B96","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1042\/bj318036","article-title":"CD28: a signalling perspective.","volume":"318","author":"Ward","year":"1996","journal-title":"Biochem J."},{"key":"B97","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways similarities, differences, and implications of their inhibition.","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol Cancer Clin Trials."},{"key":"B98","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","article-title":"CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.","volume":"19","author":"Chambers","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/ni0702-611","article-title":"CTLA-4: New insights into its biological function and use in tumor immunotherapy.","volume":"3","author":"Egen","year":"2002","journal-title":"Nat Immunol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1189\/jlb.1212621","article-title":"At the bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.","volume":"94","author":"Intlekofer","year":"2013","journal-title":"J Leukoc Biol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.00911","article-title":"The tolerogenic function of regulatory T cells in pregnancy and cancer.","volume":"10","author":"J\u00f8rgensen","year":"2019","journal-title":"Front Immunol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"14987","DOI":"10.1073\/pnas.0806075105","article-title":"CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.","volume":"105","author":"Liakou","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules24061190","article-title":"Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology.","volume":"4","author":"Lee","year":"2019","journal-title":"Molecules."},{"key":"B104","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.3748\/wjg.v20.i14.3738","article-title":"Colorectal cancer and immunity: what we know and perspectives.","volume":"20","author":"Pernot","year":"2014","journal-title":"World J Gastroenterol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"5716","DOI":"10.1158\/0008-5472.CAN-06-0261","article-title":"Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege.","volume":"66","author":"Ishida","year":"2006","journal-title":"Cancer Res."},{"key":"B106","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1006\/geno.1994.1562","article-title":"Structure and chromosomal localization of the human PD-1 gene (PDCD1).","volume":"23","author":"Shinohara","year":"1994","journal-title":"Genomics."},{"key":"B107","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","article-title":"Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.","volume":"8","author":"Agata","year":"1996","journal-title":"Int Immunol."},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000150","article-title":"Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer.","volume":"2","author":"Kitano","year":"2017","journal-title":"ESMO Open."},{"key":"B109","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.4049\/jimmunol.169.10.5538","article-title":"Expression of programmed death 1 ligands by murine T Cells and APC.","volume":"169","author":"Yamazaki","year":"2002","journal-title":"J Immunol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy.","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer."},{"key":"B111","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation.","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.4049\/jimmunol.1003208","article-title":"IFN-\u03b1 directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity.","volume":"186","author":"Terawaki","year":"2011","journal-title":"J Immunol."},{"key":"B113","first-page":"129","article-title":"Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor.","volume":"35","author":"Shindo","year":"2015","journal-title":"Anticancer Res."},{"key":"B114","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.18632\/oncotarget.13895","article-title":"PD-1 and its ligands are important immune checkpoints in cancer.","volume":"8","author":"Dong","year":"2017","journal-title":"Oncotarget."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1517\/14728222.2014.955794","article-title":"The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer.","volume":"18","author":"Henick","year":"2014","journal-title":"Expert Opin Ther Targets."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer."},{"key":"B117","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors.","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med."},{"key":"B119","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency.","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/CJI.0b013e31818403d5","article-title":"Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy.","volume":"31","author":"Tran","year":"2008","journal-title":"J Immunother."},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells.","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma.","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med."},{"key":"B124","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes.","volume":"314","author":"Morgan","year":"2006","journal-title":"Science."},{"key":"B125","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res."},{"key":"B126","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1182\/blood-2010-07-294520","article-title":"Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.","volume":"117","author":"Lamers","year":"2011","journal-title":"Blood."},{"key":"B127","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1517\/14712598.2011.573476","article-title":"Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.","volume":"11","author":"Ramos","year":"2011","journal-title":"Expert Opin Biol Ther."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy.","volume":"3","author":"Wang","year":"2016","journal-title":"Mol Ther Oncolytics."},{"key":"B129","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1182\/bloodadvances.2019000151","article-title":"Tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion.","volume":"3","author":"Bishop","year":"2019","journal-title":"Blood Adv."},{"key":"B130","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ymthe.2018.02.001","article-title":"Adoptive transfer of IL13R\u03b12-specific chimeric antigen receptor T cells creates a pro-inflammatory environment in glioblastoma.","volume":"26","author":"Pituch","year":"2018","journal-title":"Mol Ther."},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094281","article-title":"EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.","volume":"9","author":"Miao","year":"2014","journal-title":"PLoS One."},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48285-z","article-title":"A novel carcinoembryonic antigen (CEA)-targeted trimeric immunotoxin shows significantly enhanced antitumor activity in human colorectal cancer xenografts.","volume":"9","author":"L\u00e1zaro-Gorines","year":"2019","journal-title":"Sci Rep."},{"key":"B133","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering.","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature."},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013904","article-title":"Third-generation CD28\/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.","volume":"6","author":"Tang","year":"2016","journal-title":"BMJ Open."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.","volume":"128","author":"Ali","year":"2016","journal-title":"Blood."},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.5041\/RMMJ.10179","article-title":"Adoptive T cell immunotherapy for cancer.","volume":"6","author":"Perica","year":"2015","journal-title":"Rambam Maimonides Med J."},{"key":"B137","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.","volume":"36","author":"Morgan","year":"2013","journal-title":"J Immunother."},{"key":"B138","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome.","volume":"124","author":"Lee","year":"2014","journal-title":"Blood."},{"key":"B139","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia.","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med."},{"key":"B140","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s11899-018-0470-x","article-title":"CAR-T cell therapy for acute lymphoblastic leukemia: Transforming the treatment of relapsed and refractory disease.","volume":"13","author":"Pehlivan","year":"2018","journal-title":"Curr Hematol Malig Rep."},{"key":"B141","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 Results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma.","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther."},{"key":"B142","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1158\/2326-6066.CIR-16-0362","article-title":"Human GUCY2C-targeted chimeric antigen receptor (CAR)-expressing T cells eliminate colorectal cancer metastases.","volume":"6","author":"Magee","year":"2018","journal-title":"Cancer Immunol Res."},{"key":"B143","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/mt.2010.272","article-title":"T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.","volume":"19","author":"Parkhurst","year":"2011","journal-title":"Mol Ther."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.","volume":"5","author":"Hege","year":"2017","journal-title":"J Immunother Cancer."},{"key":"B145","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1089\/hum.2018.229","article-title":"Preclinical evaluation of chimeric antigen receptor\u2013modified T cells specific to epithelial cell adhesion molecule for treating colorectal cancer.","volume":"30","author":"Zhang","year":"2019","journal-title":"Hum Gene Ther."},{"key":"B146","first-page":"945","article-title":"Antitumor activity of NKG2D CAR-T cells against human colorectal cancer cells in vitro and in vivo.","volume":"9","author":"Deng","year":"2019","journal-title":"Am J Cancer Res."},{"key":"B147","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy.","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolytics."},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment.","volume":"10","author":"Martinez","year":"2019","journal-title":"Front Immunol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/path.1711680411","article-title":"Localization of CEA messenger RNA by in situ hybridization in normal colonic mucosa and colorectal adenocarcinomas.","volume":"168","author":"Abbasi","year":"1992","journal-title":"J Pathol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase I escalating-dose trial of CAR-T therapy targeting CEA + metastatic colorectal cancers.","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol Ther."},{"key":"B151","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1002\/cam4.2361","article-title":"Significantly increased anti\u2212tumor activity of carcinoembryonic antigen\u2212specific chimeric antigen receptor T cells in combination with recombinant human IL\u221212.","volume":"8","author":"Chi","year":"2019","journal-title":"Cancer Med."},{"key":"B152","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-15-0224","article-title":"Targeting YAP-dependent MDSC infiltration impairs tumor progression.","volume":"6","author":"Wang","year":"2016","journal-title":"Cancer Discov."},{"key":"B153","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.","volume":"110","author":"Feig","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B154","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1089\/10430340260355374","article-title":"Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2.","volume":"13","author":"Kershaw","year":"2002","journal-title":"Hum Gene Ther."},{"key":"B155","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.coi.2012.12.003","article-title":"cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment.","volume":"25","author":"Crespo","year":"2013","journal-title":"Curr Opin Immunol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors.","volume":"15","author":"Ma","year":"2019","journal-title":"Int J Biol Sci."},{"key":"B157","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41421-018-0066-6","article-title":"A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma\/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release.","volume":"4","author":"Xu","year":"2018","journal-title":"Cell Discov."},{"key":"B158","doi-asserted-by":"publisher","first-page":"755","DOI":"10.4049\/jimmunol.1500751","article-title":"Chimeric antigen receptor\u2013 and TCR-Modified T cells enter main street and wall street.","volume":"195","author":"Barrett","year":"2015","journal-title":"J Immunol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nbt.4090","article-title":"Driving T-cell immunotherapy to solid tumors.","volume":"36","author":"Garber","year":"2018","journal-title":"Nat Biotechnol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood."},{"key":"B161","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.","volume":"29","author":"Robbins","year":"2011","journal-title":"J Clin Oncol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1182\/bloodadvances.2019000194","article-title":"Long\u2212term safety and activity of NY-ESO\u22121 SPEAR T cells after autologous stem cell transplant for myeloma.","volume":"3","author":"Stadtmauer","year":"2019","journal-title":"Blood Adv."},{"key":"B163","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.","volume":"122","author":"Linette","year":"2013","journal-title":"Blood."},{"key":"B164","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-14-1559","article-title":"Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer.","volume":"21","author":"Kageyama","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B165","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat Med."},{"key":"B166","year":"2020"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02250","article-title":"Engineered T cell therapy for cancer in the clinic.","volume":"10","author":"Zhao","year":"2019","journal-title":"Front Immunol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"p. 755","DOI":"10.1007\/978-1-4939-3387-7_43","article-title":"Cancer vaccines: a brief overview.","author":"Thomas","year":"2016","journal-title":"Methods in Molecular Biology."},{"key":"B169","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3390\/vaccines3020467","article-title":"The promise of preventive cancer vaccines.","volume":"3","author":"Lollini","year":"2015","journal-title":"Vaccines."},{"key":"B170","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/B978-0-12-800249-0.00002-0","article-title":"Therapeutic cancer vaccines.","volume":"121","author":"Schlom","year":"2014","journal-title":"Adv Cancer Res."},{"key":"B171","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.hoc.2018.12.001","article-title":"Cancer vaccines.","volume":"33","author":"DeMaria","year":"2019","journal-title":"Hematol Oncol Clin North Am."},{"key":"B172","first-page":"229","article-title":"Evaluation of clinical data in bladder cancer immunotherapy with Connaught BCG (ImmuCyst).","volume":"77","author":"Barreto","year":"1992","journal-title":"Dev Biol Stand."},{"key":"B173","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette\u2013Gu\u00e9rin for transitional-cell carcinoma of the bladder.","volume":"325","author":"Lamm","year":"1991","journal-title":"N Engl J Med."},{"key":"B174","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Gu\u00e9rin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"484.e19","DOI":"10.1016\/j.urolonc.2016.05.033","article-title":"The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non\u2013muscle-invasive bladder cancer.","volume":"34","author":"Witjes","year":"2016","journal-title":"Urol Oncol Semin Orig Investig."},{"key":"B176","first-page":"295","article-title":"Prostatic acid phosphatase expression in human tissues.","volume":"4","author":"Graddis","year":"2011","journal-title":"Int J Clin Exp Pathol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1592\/phco.31.8.813","article-title":"Cancer immunotherapy: sipuleucel-T and beyond.","volume":"31","author":"Hammerstrom","year":"2011","journal-title":"Pharmacotherapy."},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.9249","article-title":"Adverse events associated with the use of sipuleucel-T reported to the US Food and Drug Administration\u2019s adverse event reporting system, 2010-2017.","volume":"2","author":"Dores","year":"2019","journal-title":"JAMA Netw Open."},{"key":"B179","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2217\/imt-2019-0033","article-title":"Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety.","volume":"11","author":"Raman","year":"2019","journal-title":"Immunotherapy."},{"key":"B180","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1080\/21645515.2017.1412896","article-title":"Talimogene laherparepvec: First in class oncolytic virotherapy.","volume":"14","author":"Conry","year":"2018","journal-title":"Hum Vaccines Immunother."},{"key":"B181","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma.","volume":"36","author":"Chesney","year":"2018","journal-title":"J Clin Oncol."},{"key":"B182","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41416-019-0530-6","article-title":"Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma.","volume":"121","author":"Chesney","year":"2019","journal-title":"Br J Cancer."},{"key":"B183","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00262-013-1505-8","article-title":"Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.","volume":"63","author":"Bilusic","year":"2014","journal-title":"Cancer Immunol Immunother."},{"key":"B184","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1158\/1078-0432.CCR-08-0126","article-title":"Pilot study of vaccination with recombinant CEA-MUC-1-tricom pox viral-based vaccines in patients with metastatic carcinoma.","volume":"14","author":"Gulley","year":"2008","journal-title":"Clin Cancer Res."},{"key":"B185","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-08-0276","article-title":"Combination chemotherapy and ALVAC-CEA\/B7.1 vaccine in patients with metastatic colorectal cancer.","volume":"14","author":"Kaufman","year":"2008","journal-title":"Clin Cancer Res."},{"key":"B186","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/J.CLINRE.2015.08.005","article-title":"Prognostic value of MAGE-A9 expression in patients with colorectal cancer.","volume":"40","author":"Zhan","year":"2016","journal-title":"Clin Res Hepatol Gastroenterol."},{"key":"B187","first-page":"3918","article-title":"Overexpression of MAGE-D4 in colorectal cancer is a potentially prognostic biomarker and immunotherapy target.","volume":"7","author":"Zhang","year":"2014","journal-title":"Int J Clin Exp Pathol."},{"key":"B188","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/SLA.0b013e318292919e","article-title":"A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.","volume":"258","author":"Morse","year":"2013","journal-title":"Ann Surg."},{"key":"B189","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1586\/14760584.7.7.963","article-title":"Strategies used for MUC1 immunotherapy: human clinical studies.","volume":"7","author":"Tang","year":"2008","journal-title":"Expert Rev Vaccines."},{"key":"B190","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-4-1","article-title":"A phase I trial of pox PSA vaccines (PROSTVAC\u00ae-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOMTM) in patients with prostate cancer.","volume":"4","author":"DiPaola","year":"2006","journal-title":"J Transl Med."},{"key":"B191","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/s0264-410x(96)00238-1","article-title":"Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.","volume":"15","author":"Hodge","year":"1997","journal-title":"Vaccine."},{"key":"B192","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1158\/0008-5472.CAN-06-3045","article-title":"Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.","volume":"67","author":"Saha","year":"2007","journal-title":"Cancer Res."},{"key":"B193","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.omto.2018.12.004","article-title":"Recombinant AAV-CEA tumor vaccine in combination with an immune adjuvant breaks tolerance and provides protective immunity.","volume":"12","author":"Hensel","year":"2019","journal-title":"Mol Ther Oncolytics."},{"key":"B194","first-page":"947","article-title":"BCG immunotherapy for transitional-cell carcinoma in situ of the bladder.","volume":"9","author":"Lamm","year":"1995","journal-title":"Oncology (Williston Park)."},{"key":"B195","first-page":"2175","article-title":"Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.","volume":"6","author":"Burch","year":"2000","journal-title":"Clin Cancer Res."},{"key":"B196","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/pros.20040","article-title":"Immunotherapy (APC8015, provenge\u00ae) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial.","volume":"60","author":"Burch","year":"2004","journal-title":"Prostate."},{"key":"B197","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.","volume":"24","author":"Small","year":"2006","journal-title":"J Clin Oncol."},{"key":"B198","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1158\/1078-0432.CCR-10-3223","article-title":"Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.","volume":"17","author":"Beer","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B199","doi-asserted-by":"publisher","first-page":"6737","DOI":"10.1158\/1078-0432.CCR-06-0759","article-title":"A phase I study of OncoVEX GM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.","volume":"12","author":"Hu","year":"2006","journal-title":"Clin Cancer Res."},{"key":"B200","doi-asserted-by":"publisher","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","article-title":"Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.","volume":"27","author":"Senzer","year":"2009","journal-title":"J Clin Oncol."},{"key":"B201","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.","volume":"28","author":"Kantoff","year":"2010","journal-title":"J Clin Oncol."},{"key":"B202","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1200\/JCO.2016.69.7748","article-title":"Revised overall survival analysis of a phase II, randomized, double-blind, controlled study of PROSTVAC in men with metastatic castration-resistant prostate cancer.","volume":"35","author":"Kantoff","year":"2017","journal-title":"J Clin Oncol."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.","volume":"37","author":"Gulley","year":"2019","journal-title":"J Clin Oncol."},{"key":"B204","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy.","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br J Cancer."},{"key":"B205","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00005-017-0491-5","article-title":"Immunotherapy as an option for cancer treatment.","volume":"66","author":"Rusch","year":"2018","journal-title":"Arch Immunol Ther Exp (Warsz)."},{"key":"B206","doi-asserted-by":"publisher","first-page":"7204","DOI":"10.18632\/oncotarget.23208","article-title":"Inflammatory responses and inflammation-associated diseases in organs.","volume":"9","author":"Chen","year":"2018","journal-title":"Oncotarget."},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.74550","author":"Ferreira","year":"2019","journal-title":"Cytokines and Interferons: Types and Functions. Autoantibodies and Cytokines."},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1433982","article-title":"Trial watch: immunostimulation with recombinant cytokines for cancer therapy.","volume":"7","author":"Garc\u00eda-Mart\u00ednez","year":"2018","journal-title":"Oncoimmunology."},{"key":"B209","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1158\/1078-0432.CCR-14-1520","article-title":"The high-dose aldesleukin \u201cselect\u201d trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.","volume":"21","author":"McDermott","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B210","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/annonc\/mdw225","article-title":"Adjuvant treatment with pegylated interferon \u03b1-2a versus low-dose interferon \u03b1-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial.","volume":"27","author":"Eigentler","year":"2016","journal-title":"Ann Oncol."},{"key":"B211","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/j.1365-2141.1992.tb04559.x","article-title":"Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia.","volume":"80","author":"Habermann","year":"1992","journal-title":"Br J Haematol."},{"key":"B212","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1080\/10428190601175393","article-title":"Phase II, randomized, multicenter, comparative study of peginterferon\u2013\u03b1\u20132a (40 kD) (Pegasys\u00ae) versus interferon \u03b1-2a (Roferon\u00ae-A) in patients with treatment-na\u00efve, chronic-phase chronic myelogenous leukemia.","volume":"48","author":"Lipton","year":"2007","journal-title":"Leuk Lymphoma."},{"key":"B213","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/bjc.1992.372","article-title":"Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers.","volume":"66","author":"Biesma","year":"1992","journal-title":"Br J Cancer."},{"key":"B214","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMoa003013","article-title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.","volume":"345","author":"Flanigan","year":"2001","journal-title":"N Engl J Med."},{"key":"B215","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/sj.leu.2403217","article-title":"Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: A phase III study.","volume":"18","author":"Michallet","year":"2004","journal-title":"Leukemia."},{"key":"B216","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/1346-8138.13338","article-title":"Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.","volume":"43","author":"Yamazaki","year":"2016","journal-title":"J Dermatol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01624\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:28:52Z","timestamp":1600388932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01624\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":216,"alternative-id":["10.3389\/fimmu.2020.01624"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.01624","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,18]]},"article-number":"1624"}}